Nerandomilast is both effective and well-tolerated, representing a “major step forward for the treatment of progressive pulmonary fibrosis (PPF),” with its effect on clinical outcomes sustained over 76 weeks, according to findings from the…
Nerandomilast is both effective and well-tolerated, representing a “major step forward for the treatment of progressive pulmonary fibrosis (PPF),” with its effect on clinical outcomes sustained over 76 weeks, according to findings from the…